INNATE PHARMA

IPH - FR0010331421 SRD PEA PEA-PME
3.248 € +1.95 % Temps réel Euronext Paris

NEWS explosive

02/05/2011 par titi7511 0
gros paiement d'étape le 01 mars donc compris dans le t1 2011+ news conference



|Cercle Finance le 01/03/2011 à 10:10

Innate Pharma : a reçu un paiement d'étape pour l'IPH 2201.



(CercleFinance.com) - Innate Pharma a annoncé hier soir qu'une demande d'essai clinique en Europe

a été déposée par Novo Nordisk A/S pour IPH 2201 (NN8765), ce qui a déclenché un paiement

d'étape ' significatif ' pour Innate Pharma.



Dans son communiqué, la société biopharmaceutique rappelle qu'IPH 2201 est un anticorps

humanisé, issu de sa collaboration avec Novo Nordisk A/S, et développé dans l'inflammation et

les maladies auto-immunes.



' IPH 2201 pourrait être le troisième anticorps monoclonal issu de notre collaboration avec Novo

Nordisk A/S à entrer en essai clinique, après IPH 2101 et NN8555 ', a déclaré Hervé Brailly,

le Président du Directo ire d'Innate Pharma.



IPH 2201 devrait en effet entrer en essai clinique de Phase I en 2011. Innate Pharma est éligible

à des paiements d'étape pour le développement de IPH 2201 et à des royalties sur les ventes

futures.



+

A PHASE I TRIAL OF IPH-2101, A NOVEL ANTI-INHIBITORY KIR ANTIBODY, IN PATIENTS WITH MULTIPLE MYELOMA





D. BENSON(1), C. BAKAN(1), C. HOFMEISTER(1), Y. EFEBERA(1), A. SUVANNASANKHA(2), S. JAGGANATH(3), R.

ABONOUR(2), A. CHARI(3), S. PADMANABAN(4), F. ROMAGNE(5), P. ANDRE(5), S. BLANCHET(5), R. BUFFET(5),

M. CALIGIURI(1), S. FARAG(2)



(1) The Ohio State University, COLUMBUS, UNITED STATES ; (2) Indiana University Cancer Center,

INDIANAPOLIS, UNITED STATES ; (3) Mt Sinai Cancer Center, NEW YORK, UNITED STATES ; (4) Cancer

Treatment and Research Center, SAN ANTONIO, UNITED STATES ; (5) Innate Pharma, MARSEILLE, FRANCE









Background: Multiple myeloma (MM) cells upregulate MHC class I as ligands to inhibitory killer

immunoglobulin-like receptors (KIR) on natural killer (NK) cells. IPH-2101, an anti-KIR antibody,

enhances NK cell function against cancer by disrupting inhibitory KIR/ligand relationship. Methods:

A dose-escalation study was conducted in previously treated patients (pts) with MM in 7 cohorts

(0.0003 to 3mg/kg IV q28-d for up to 4 cycles) in a 3+3 design (with a 7-pt extension at 3mg/kg in

pts with one prior therapy). Pharmacokinetic (PK), pharmacodynamic (PD), safety and biologic data

were collected. Results: 32 pts (med age = 61, prior therapies = 1-7) were treated. Full KIR

saturation over dosing interval was achieved without DLT. The median number of IPH-2101 doses

received was 2, 31% of pts received all 4 doses. 12% of AEs were reported (mild or moderate)

“possibly” or “probably” related to IPH-2101. 1 SAE occurred (acute renal failure). PK and

PD data closely approximated preclinical models, IPH-2101 had no effect on NK cell maturation but

enhanced ex vivo NK cell cytotoxicity against MM. 12 pts had stable disease. Conclusions: IPH-2101

is safe and tolerable with doses that achieve full KIR saturation over the dosing interval. Cmax and

KIR occupancy correlate, and IPH-2101 enhances NK cell cytotoxicity against MM. 38% of pts achieved

a best response of stable disease. Phase II studies in maintenance after autologous SCT and in

smoldering MM as well as a phase I/II trial of IPH-2101 and lenalidomide are underway. Final results

will be presented.

TradingSat
Portefeuille Trading
+333.50 % vs -3.37 % pour le CAC 40
Performance depuis le 28 mai 2008

Newsletter bfm bourse

Recevez gratuitement chaque matin la valeur du jour sélectionnée par Logo TradingSat